Cancer-focused Orionis debuts with small molecule discovery deal with Novartis

Orionis emerged from stealth Thursday, partnering with Novartis and unveiling its cell-based protein interaction screening platform.

Under the four-year collaboration, Novartis AG (NYSE:NVS; SIX:NOVN) and Orionis Biosciences will use the latter’s Allo-Glue platform to map out interactions between small molecules and proteins to discover and develop therapies such as protein degraders. The collaboration has no specific therapeutic area of focus, Orionis President and CEO Niko Kley told BioCentury...